NREP
NEW REPRESENTATIVE AT IB RECEIVED
09/28/2024
Back to search
Official data from USPTO
LAVA THERAPEUTICS
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: US
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
31
Latest update
09/28/2024
Classification
Registered
Trademark type
Combined
Nice classes
1, 5, 42, 44
Filing date
09/07/2021
Registration date
01/24/2023
Expiration date
-
Recommended action
Perform a full collision analysis and validate classes before any filing or trademark investment.
Next step
These are the details of the registration process. Even so, constant monitoring is what ensures peace of mind that your main asset remains protected.
Complete case details
Structured fields from the responsible authority and the official record.
Status date
01/24/2023
Last transaction
01/24/2023
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
3
Owner type
32
Owner location
NL
Examiner
MASON, JARED MICHAEL
Law office
N10
Current location
PUBLICATION AND ISSUE SECTION
Mark description
The mark consists of the purple larger-sized stylized wording "LAVA", below which is the purple smaller-sized stylized wording "THERAPEUTICS". To the right of this is a tilted square with three lines breaking it up. The square is shaded from yellow to orange from top to bottom.
Holders and representatives
Holders
Lava Therapeutics N.V.
Representatives
Robert R. Baron, Jr. Ballard Spahr LLP
Technical classification
Nice Classes
Class 1Class 5Class 42Class 44
Vienna Codes
No Vienna codes available.
Goods and services
Class 1
Antibodies for scientific and research use; proteinsenzymesdiagnostic reagentschemical and biochemical preparations and substances for use in the manufacture of medicines
Class 5
Pharmaceutical preparations for T Cell therapy; pharmaceutical products for the prevention and treatment of cancer; immunotherapy productspharmaceutical preparations for the treatment of cancerautoimmune diseasesimmunological disorders; biological preparations for the treatment of cancerautoimmune diseasesimmunological disorders; chemical and biochemical preparations and substances for medical purposes for treatment or diagnosis of cancerautoimmune diseases and immunological disorders; antibodies and libraries of antibodies for medical purposesfor treatment or diagnosis of cancerautoimmune diseases and immunological disorders
Class 42
Bio-technology and scientific servicesscientific and medical research and development services relating to bio-technology and science in the field of antibodiesproteins and enzymes; pharmaceutical research and development; biological and bio-technology analysis services; scientific and medical laboratory services; biochemistry research servicesscientific and medical research in the fields of antibodiesprotein and enzyme evolving services; biochemistry research servicesscientific and medical research in the fields of antibodiesprotein and enzyme cataloging and antibodiesprotein and enzyme library services; scientific and medical laboratory services relating to the production of antibodiesproteins and enzymes
Class 44
Providing health information about the treatment or diagnosis of cancerautoimmune diseases and immunological disorders via a website
Publications
History of USPTO decisions and trademark events.
31 publications found
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
05/23/2023
FICS
FINAL DISPOSITION NOTICE SENT TO IB
05/03/2023
FIMP
FINAL DISPOSITION PROCESSED
05/03/2023
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
04/24/2023
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
01/24/2023
R.PR
REGISTERED-PRINCIPAL REGISTER
01/24/2023
NREP
NEW REPRESENTATIVE AT IB RECEIVED
12/09/2022
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
11/08/2022
PUBO
PUBLISHED FOR OPPOSITION
11/08/2022
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
10/19/2022
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
10/03/2022
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
09/20/2022
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
09/20/2022
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
09/20/2022
RFNT
REFUSAL PROCESSED BY IB
06/22/2022
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
05/26/2022
RFRR
REFUSAL PROCESSED BY MPU
05/26/2022
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
04/23/2022
CNRT
NON-FINAL ACTION WRITTEN
04/22/2022
DOCK
ASSIGNED TO EXAMINER
04/21/2022
ADCH
CHANGE OF NAME/ADDRESS REC'D FROM IB
03/04/2022
NREP
NEW REPRESENTATIVE AT IB RECEIVED
02/26/2022
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
01/19/2022
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
01/19/2022
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
01/19/2022
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
01/19/2022
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
01/19/2022
MAFR
APPLICATION FILING RECEIPT MAILED
12/14/2021
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
12/10/2021
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
12/09/2021
Continuous trademark protection
Get notified about every new filing that threatens LAVA THERAPEUTICS or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.